Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Savior Lifetec Corp. (4167.TWO)
TWD21.30
+0.70 (+3.40%)
TW TWO Healthcare Biotechnology
Address
No. 1, Nanke 6th Road 35053
Tainan City, TW
Tainan City, TW
CEO
Yung-Fa Chen
Website
saviorlifetec.com.tw/en
IPO
2012-12-21
ISIN TW0004167002
Description
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan City, Taiwan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD21.30
+0.70 (+3.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.11
Float Shares
258.51M
Free Float %
83.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.53% | +2.14% | -6.60% | +0.00% | +3.80% | +3.80% | -6.37% | +12.02% | -28.17% | -12.59% | -24.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21.30
DCF (Unlevered)
36.37
+70.7%
DCF (Levered)
22.25
+4.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.75
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-1.3% Q1'26: -11.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+201.8% ★ Q1'26: -76.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-7.0% Q1'26: -66.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+15.2% ★ Q1'26: +8.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+7.7% ★ Q1'26: +3.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.5% ★ Q1'26: -2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.67× ★ Q1'26: 2.40× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.12B
est: 1.25B (-10.6%)
|
1.53B
est: 1.72B (-11.0%)
|
1.62B
est: 1.69B (-4.4%)
|
1.10B
est: 1.53B (-27.8%)
|
1.32B
est: 1.30B (+1.8%)
|
1.83B
est: 1.83B (+0.0%)
|
1.74B
est: 2.04B (-14.4%)
|
1.27B
est: 2.15B (-41.1%)
|
1.22B
est: 2.15B (-43.4%)
|
1.20B
est: 1.69B (-29.0%)
|
1.69B
1.69B – 1.69B
+0.0% YoY
|
1.53B
1.53B – 1.53B
-9.7% YoY
|
1.30B
1.30B – 1.30B
-15.3% YoY
|
1.83B
1.83B – 1.83B
+41.1% YoY
|
2.04B
2.04B – 2.04B
+11.4% YoY
|
2.15B
2.15B – 2.15B
+5.6% YoY
|
| EBITDA |
-260.47M
est: 274.86M (-194.8%)
|
35.55M
est: 377.43M (-90.6%)
|
251.95M
est: 371.08M (-32.1%)
|
-135.49M
est: 335.13M (-140.4%)
|
247.50M
est: 283.84M (-12.8%)
|
496.77M
est: 400.45M (+24.1%)
|
263.33M
est: 446.26M (-41.0%)
|
260.73M
est: 471.24M (-44.7%)
|
314.02M
est: 692.08M (-54.6%)
|
274.34M
est: 544.97M (-49.7%)
|
544.97M
544.97M – 544.97M
+0.0% YoY
|
492.18M
492.18M – 492.18M
-9.7% YoY
|
416.86M
416.86M – 416.86M
-15.3% YoY
|
588.11M
588.11M – 588.11M
+41.1% YoY
|
655.38M
655.38M – 655.38M
+11.4% YoY
|
692.08M
692.08M – 692.08M
+5.6% YoY
|
| EBIT |
-463.83M
est: 99.10M (-568.0%)
|
-171.77M
est: 136.09M (-226.2%)
|
105.99M
est: 133.79M (-20.8%)
|
-342.01M
est: 120.83M (-383.0%)
|
27.01M
est: 102.34M (-73.6%)
|
275.16M
est: 144.38M (+90.6%)
|
27.82M
est: 160.90M (-82.7%)
|
52.00M
est: 169.91M (-69.4%)
|
186.88M
est: 675.47M (-72.3%)
|
182.24M
est: 531.89M (-65.7%)
|
531.89M
531.89M – 531.89M
+0.0% YoY
|
480.37M
480.37M – 480.37M
-9.7% YoY
|
406.85M
406.85M – 406.85M
-15.3% YoY
|
573.99M
573.99M – 573.99M
+41.1% YoY
|
639.66M
639.66M – 639.66M
+11.4% YoY
|
675.47M
675.47M – 675.47M
+5.6% YoY
|
| Net Income |
-493.79M
est: -675.10M (+26.9%)
|
-207.70M
est: -261.83M (+20.7%)
|
22.27M
est: 102.32M (-78.2%)
|
-359.55M
est: 84.27M (-526.7%)
|
-44.05M
est: -36.25M (-21.5%)
|
250.94M
est: 254.72M (-1.5%)
|
-4.76M
est: 28.63M (-116.6%)
|
20.62M
est: 314.93M (-93.5%)
|
182.38M
est: 307.15M (-40.6%)
|
533.64M
est: 99.80M (+434.7%)
|
99.80M
99.80M – 99.80M
+0.0% YoY
|
82.19M
82.19M – 82.19M
-17.6% YoY
|
-35.35M
-35.35M – -35.35M
-143.0% YoY
|
248.43M
248.43M – 248.43M
+802.8% YoY
|
27.92M
27.92M – 27.92M
-88.8% YoY
|
307.15M
307.15M – 307.15M
+1,000.0% YoY
|
| SGA |
125.24M
est: 115.07M (+8.8%)
|
127.28M
est: 158.01M (-19.5%)
|
120.00M
est: 155.35M (-22.8%)
|
144.50M
est: 140.30M (+3.0%)
|
100.76M
est: 118.83M (-15.2%)
|
137.07M
est: 167.65M (-18.2%)
|
114.40M
est: 186.83M (-38.8%)
|
106.12M
est: 197.29M (-46.2%)
|
152.74M
est: 221.23M (-31.0%)
|
157.05M
est: 174.20M (-9.8%)
|
174.20M
174.20M – 174.20M
+0.0% YoY
|
157.33M
157.33M – 157.33M
-9.7% YoY
|
133.25M
133.25M – 133.25M
-15.3% YoY
|
187.99M
187.99M – 187.99M
+41.1% YoY
|
209.50M
209.50M – 209.50M
+11.4% YoY
|
221.23M
221.23M – 221.23M
+5.6% YoY
|
| EPS |
-2.49
est: -2.12 (-17.3%)
|
-0.85
est: -0.82 (-3.3%)
|
0.09
est: 0.32 (-73.5%)
|
-1.40
est: 0.26 (-628.5%)
|
-0.16
est: -0.11 (-40.4%)
|
0.84
est: 0.80 (+4.9%)
|
-0.02
est: 0.09 (-116.7%)
|
0.07
est: 0.99 (-93.4%)
|
0.57
est: 0.99 (-42.4%)
|
1.72
est: 0.32 (+434.7%)
|
0.32
0.32 – 0.32
+0.0% YoY
|
0.26
0.26 – 0.26
-17.6% YoY
|
-0.11
-0.11 – -0.11
-143.0% YoY
|
0.80
0.80 – 0.80
+802.8% YoY
|
0.09
0.09 – 0.09
-88.8% YoY
|
0.99
0.99 – 0.99
+1,000.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-29.11M
OE per share TTM
-0.07
Owner's Yield
-0.51%
Maintenance CapEx ratio
83.61%
Maint CapEx / Avg PPE
108.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 23 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 17.0K | 0.42% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 21.7K | 0.56% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 582.8K | 0.06% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 75.7K | 0.46% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 237.8K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 186.8K | 0.29% |
| 7 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 3.3K | 0.33% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.0K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.3K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.89M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
486.0K
Shares Outstanding
310.44M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chia-Chu Chou | Representative Director & Assistant Vice President | 2M | male |
| Chih-Fang Chen | President & Managerial Officer | — | male |
| Fang Zhen Xu | Head of Internal Audit | — | — |
| Kuo-Wei Lin | Financial Officer & Accounting Supervisor | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4167.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
